Droplet Digital PCR Speeds Pathogen Detection in Febrile Leukopenia Patients

For patients undergoing treatment for blood cancers, fever is never just a fever. When chemotherapy, hematopoietic stem cell transplantation, or immunosuppressive therapy drives white blood cell counts below 4.0 × 10⁹ cells per liter, the body’s primary defense against infection is stripped away, and a rising temperature can signal a bloodstream infection that becomes life-threatening within hours. Clinicians facing febrile leukopenia must act fast, yet the diagnostic tools they traditionally rely on are frustratingly slow. Blood cultures, the historical gold standard for identifying bacterial and fungal pathogens in the blood, can take days to yield results, and their sensitivity drops precisely in the patients who need them most, because these individuals have few circulating immune cells and are often already receiving empiric antibiotics that suppress bacterial growth in the culture bottle. A new retrospective cohort study published in BMC Infectious Diseases by Jingjing Liu, Ningning Zhu, Baodong Ye, Yu Zhang and colleagues at The First Affiliated Hospital of Zhejiang Chinese Medical University in Hangzhou now offers quantitative evidence that droplet digital polymerase chain reaction, or ddPCR, can close this diagnostic gap, detecting pathogens faster and more often than conventional methods while potentially helping physicians rein in antibiotic use.

The technology behind ddPCR is elegantly suited to the problem of finding scarce pathogen DNA in a noisy clinical sample. In a conventional quantitative PCR reaction, a single tube of sample is amplified and the accumulating fluorescence is measured cycle by cycle, which makes the result sensitive to inhibitors, competing background DNA, and the precise efficiency of the amplification reaction. Droplet digital PCR takes a fundamentally different approach: the sample is partitioned into tens of thousands of microscopic water-in-oil droplets, each of which functions as an independent micro-reactor. After thermal cycling, each droplet is counted as either positive, meaning it contained at least one copy of the target sequence and fluoresced, or negative. Because the reactions are binary, the instrument can apply Poisson statistics to the fraction of positive droplets and calculate the absolute number of target molecules in the original sample without any standard curve or reference material. This partitioning also dilutes out inhibitors and makes the method exceptionally tolerant of low target concentrations, which is exactly the situation in a leukopenic patient whose blood may harbor only trace amounts of circulating pathogen DNA.

The Hangzhou team put this capability to the test in a study conducted between March 2024 and March 2025. They enrolled febrile patients with hematological diseases and leukopenia who underwent ddPCR testing alongside blood culture, the (1,3)-β-D-glucan assay used to screen for invasive fungal infection, and the galactomannan assay used to detect Aspergillus antigens. In total, the analysis covered 253 samples drawn from 172 inpatients. The researchers divided the cohort into two groups for their exploratory analysis: 47 patients whose antimicrobial therapy was informed by ddPCR results, forming what the authors call the ddPCR-participated antimicrobial therapy group, and 206 patients who received experienced standard care without ddPCR input. The primary objective was to measure how well ddPCR performed as a diagnostic test compared with the conventional microbiological arsenal; the secondary, exploratory objective was to see whether incorporating ddPCR results into treatment decisions changed antibiotic consumption or clinical outcomes.

The headline diagnostic finding was unambiguous. ddPCR achieved a significantly higher pathogen detection rate than blood culture, the β-D-glucan test, and the galactomannan test alike. This matters because each of the conventional assays has well-known blind spots: blood culture misses organisms that are difficult to grow or that have been suppressed by prior antibiotics, while the fungal antigen tests detect only specific molecular signatures and can produce false positives in certain patient populations. By directly amplifying pathogen DNA, ddPCR sidesteps the requirement that an organism be viable or that it express a particular antigen, allowing it to flag bacterial and fungal signatures that other assays never see. For a clinician managing a neutropenic fever, that difference can translate into hours or days of earlier, more targeted therapy.

To move beyond simple detection rates, the researchers benchmarked ddPCR against a clinically adjudicated diagnosis of bloodstream infection, a reference classification determined by expert review of the full clinical picture rather than by any single laboratory test. Receiver operating characteristic analysis, which plots true-positive rate against false-positive rate across all possible test thresholds, showed that ddPCR delivered the highest diagnostic performance of the assays evaluated, with an area under the curve of 0.796 and a 95 percent confidence interval spanning 0.703 to 0.889. In head-to-head statistical comparisons, ddPCR significantly outperformed C-reactive protein, a widely used but nonspecific inflammatory marker, with a p value of 0.011, and outperformed interferon-based testing with a p value of 0.001. Its advantage over procalcitonin, another commonly measured infection biomarker, did not reach statistical significance, with a p value of 0.137, suggesting that ddPCR and procalcitonin may occupy complementary rather than competing roles at the bedside.

The exploratory analysis of antimicrobial stewardship produced what may prove to be the study’s most consequential observation. When physicians received ddPCR results and modified antimicrobial regimens accordingly, patients incurred lower antibiotic expenditure, and this effect was particularly pronounced among patients with hematological malignancies, reaching statistical significance at p = 0.020. The economics of antimicrobial therapy in hematology wards are far from trivial: broad-spectrum empiric regimens often combine anti-pseudomonal beta-lactams, glycopeptides, and antifungals, some of which cost hundreds of dollars per day, and they are frequently continued for days longer than necessary in the absence of a confirmed pathogen. A rapid molecular result that either identifies a specific organism, allowing therapy to be narrowed, or reassuringly rules out bacterial and fungal DNA, allowing empiric coverage to be de-escalated, gives the stewardship team an objective anchor for those decisions. The authors are careful to frame this as an exploratory association rather than proof of causation, since the retrospective design and the self-selected nature of the ddPCR-tested group could introduce confounding, but the signal is consistent with the mechanistic logic of stewardship programs worldwide.

The study’s design deserves scrutiny alongside its results. As a single-center retrospective cohort, it reflects the testing patterns and prescribing culture of one large hematology department in eastern China, and the 47 patients in the ddPCR-informed group were not randomized. The authors also relied on a composite reference standard for adjudicating infections, which is a pragmatic necessity in this population where no single test is definitive, but it means the diagnostic performance figures should be read as performance against expert clinical judgment rather than against microbiological certainty. The team explicitly calls for prospective multicenter studies to confirm the findings and to define precisely which patients benefit most from ddPCR-guided management. Those caveats notwithstanding, the study was approved by the hospital’s ethics committee, conducted under the Declaration of Helsinki, and supported by funding from the Zhejiang Provincial Natural Science Foundation, the National Natural Science Foundation of China, and the province’s “Leading Geese” research and development program, lending it institutional and financial transparency.

The broader context makes the timing of this work significant. Hematology has been an early adopter of molecular diagnostics, with metagenomic next-generation sequencing increasingly used to cast a wide net for pathogens in immunocompromised patients. But metagenomic sequencing remains expensive, computationally demanding, and slow relative to the pace of clinical deterioration in febrile neutropenia. ddPCR occupies a different niche: it is targeted, requiring the laboratory to select assays for suspected pathogens, yet it delivers absolute quantification within hours at a fraction of the cost, and its digital readout makes results interpretable even at very low pathogen loads. For patients receiving CAR-T cell therapy or intensive induction chemotherapy, in whom the window between fever and sepsis can be measured in hours, that speed-versus-breadth trade-off may be exactly the right one. The Hangzhou results suggest ddPCR could serve as a rapid first-line molecular screen that complements, rather than replaces, both culture and sequencing.

What emerges from the study is a portrait of diagnostics catching up with clinical reality. Febrile leukopenia has long forced physicians into a dilemma: treat empirically and broadly to protect a vulnerable patient, or wait for laboratory confirmation and risk losing the race against sepsis. The ddPCR data from Liu, Zhu, Zhang, Ye and their colleagues indicate that this dilemma is not immutable. A test that detects pathogens more often than blood culture, outperforms standard inflammatory markers for adjudicated bloodstream infection, and is associated with reduced antibiotic spending in the sickest patients addresses the problem from three directions at once, improving diagnostic yield, sharpening clinical decision-making, and supporting antimicrobial stewardship in an era when antibiotic resistance makes every unnecessary day of broad-spectrum therapy a cost to the individual and to the community. If prospective multicenter trials bear out these findings, droplet digital PCR could become a routine component of the febrile leukopenia workup, turning a diagnostic waiting game into a same-day answer.

Subject of Research: Droplet digital PCR for pathogen detection and antimicrobial stewardship in febrile leukopenic patients with hematological diseases

Article Title: Clinical application of ddPCR-assisted antimicrobial stewardship in febrile leukopenia patients

Article References: Liu, J., Zhu, N., Le, M., Dong, N., Tan, Z., Wang, R., Liu, Q., Zhang, K., Qian, L., Shen, Y., Liu, M., Du, P., Li, T., Ge, H., Bei, L., Zhao, Y., Yu, Q., Liu, W., Wu, D., … Ye, B. (2026). Clinical application of ddPCR-assisted antimicrobial stewardship in febrile leukopenia patients. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14523-9

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14523-9

Keywords: ddPCR, febrile leukopenia, bloodstream infection, antimicrobial stewardship, hematological malignancies, pathogen detection, blood culture, diagnostics, immunocompromised patients, BMC Infectious Diseases, Clinical, application